Last reviewed · How we verify
Ustekinumab and Upadacitinib
At a glance
| Generic name | Ustekinumab and Upadacitinib |
|---|---|
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study (PHASE3)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
- Ibd CAncer and seRious Infections in France (I-CARE 2)
- Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: